UniXell Biotechnology Celebrates Dual FDA and NMPA Approval for Parkinson's Treatment#China#Shanghai#Parkinson's_Disease#iPSC_therapy#UniXell
UniXell Biotechnology Celebrates Dual FDA and NMPA Approval for Parkinson's Treatment
UniXell Biotechnology has achieved FDA IND clearance for UX-DA003, marking a major milestone for Parkinson's disease treatment, highlighting dual success in U.S. and China.
third-news.com
June 24, 2026 at 6:18 AM
UniXell Biotechnology Celebrates Dual FDA and NMPA Approval for Parkinson's Treatment#China#Shanghai#Parkinson's_Disease#iPSC_therapy#UniXell
XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P#China#Suzhou#XellSmart#iPSC_therapy#MSA-P
XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P
XellSmart secures its fourth consecutive IND clearance from the US FDA and China's NMPA for a new cell therapy targeting MSA-P, showcasing its innovative approach.
third-news.com
March 2, 2026 at 2:54 PM
XellSmart Achieves Fourth Consecutive Regulatory Approval for Breakthrough Cell Therapy for MSA-P#China#Suzhou#XellSmart#iPSC_therapy#MSA-P
BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting#United_States#San_Diego#iPSC_therapy#BrainXell#BXT-110
BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting
BrainXell is set to showcase innovative findings on iPSC-derived therapies for Parkinson's Disease, focusing on BXT-110 during the 2025 SfN meeting in San Diego.
third-news.com
November 15, 2025 at 4:12 PM
BrainXell Unveils Groundbreaking Research on iPSC Therapy at 2025 SfN Meeting#United_States#San_Diego#iPSC_therapy#BrainXell#BXT-110
XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials#China#Suzhou#Spinal_Cord_Injury#XellSmart#iPSC_therapy
XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials
XellSmart's innovative allogeneic iPSC-derived cell therapy has received FDA approval for clinical trials, offering hope for spinal cord injury treatment.
third-news.com
May 26, 2025 at 1:02 AM
XellSmart's Breakthrough Spinocord Injury Therapy Achieves FDA Approval for Clinical Trials#China#Suzhou#Spinal_Cord_Injury#XellSmart#iPSC_therapy